[Therapeutic strategy of newly developing medicines for disseminated intravascular coagulation--activated protein C and thrombomodulin].
Thrombomodulin-protein C system plays a very important role for the blood fluidity converting thrombin from a procoagulant protease to an anticoagulant and degrading activated factors Va and V III a. By their properties, both thrombomodulin and protein C may be expected for therapeutic medicines in DIC and some thromboembolic disorders. We reviewed and evaluated the probability of activated protein C and thrombomodulin for DIC treatment. Both appeared to be a very expectant for DIC medicine based on the preliminary clinical or experimental trials. Activated protein C is now under clinical trial in DIC. Recombinant thrombomodulin is also going to start its clinical trial in very near future.
Maruyama
I
I
Department of Laboratory Medicine, Kagoshima University School of Medicine.
D000818:Animals; D001777:Blood Coagulation; D004211:Disseminated Intravascular Coagulation / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000378:metabolism / Q000502:physiology; D006801:Humans; D011486:Protein C / Q000502:physiology / Q000627:therapeutic use*; D011956:Receptors, Cell Surface / Q000378:metabolism / Q000502:physiology; D018179:Receptors, Thrombin; D011994:Recombinant Proteins
D011486:Protein C; D011956:Receptors, Cell Surface; D018179:Receptors, Thrombin; D011994:Recombinant Proteins